Calcification is a common problem in many pathologic and physiologic conditions, such as ageing, dyslipidemia, diabetes, genetic disorders, and illnesses with abnormalities in calcium metabolism. Vascular calcification is more prevalent, occurs early, and adds to the significantly higher cardiovascular risk in people with chronic kidney illnesses. One of the calcification inhibitors, fetuin A, has a reduced amount in CKD individuals. Therefore, in term of appreciated the importance of fetuin A as a circulating glycoprotein, in preventing ectopic calcium phosphate mineralisation, this review would aim to highlight the independent Fetuin A role associated factor to the risk of vascular inflammation.